The Cannabis Company That Won't Mix Work With Pleasure
A limited supply of cannabis in the U.S. means those resources have to be divvied up carefully.
For Cronos Group, that means keeping its medical and recreational marijuana operations in completely different verticals, CEO Michael Gorenstein told Cheddar. That ensures patients’ needs are prioritized over those of recreational users.
“If you think about building a town, and you have a limited amount of building supplies, we want to make sure that we’re building a hospital before we’re building the bar,” he said.
Canada-based Cronos Group started trading on the NASDAQ on Tuesday, making it the first marijuana company to list on a major U.S. market.
“It’s a big milestone not just for us but for the entire industry,” said Gorenstein. “[It] just continues to show the acceptance that the cannabis industry is getting.”
And the industry does seem to be growing at break-neck speed. Arcview, a leading researcher of the cannabis market, stated in a [recent report](https://arcviewgroup.com/product/5th-edition/) that the industry brought in $9.7 billion in sales in 2017, and that number could grow to over $25 billion by 2021.
For the full interview, [click here](https://cheddar.com/videos/inside-the-first-cannabis-company-to-list-on-nasdaq).
On a day where the Dow and Russell 2000 each closed more than 3% lower, Melissa Armo, founder and owner of The Stock Swoosh, says Wednesday's big sell-off could extend into after-hours trading. She joined Cheddar News' Closing Bell for more.
At a time when banks in countries like Australia and Spain are offering customers cryptocurrency assets for the first time, Josh Goodbody, COO of Qredo, believes we're going to see more financial institutions across the world unveil their crypto solutions this year after developing them behind the scenes last year. He joined Cheddar News' Closing Bell to discuss.
Americans looking to purchase at-home COVID-19 tests will now have to shell out a bit more money after an agreement expired between the White House and companies to sell the tests at cost. The price of Abbot's BinaxNow test kit from October to December was $14 apiece; on Tuesday, Walmart's website listed the test for $19.88, and Kroger listed the tests for $23.99. Carbon Health Regional Clinical Director Dr. Bayo Curry-Winchell joined Cheddar News' Closing Bell to discuss the impact higher prices will have as the nation experiences another surge in cases.
Natalia Abrams, President of the Student Debt Crisis Center, discusses how the extension impacts borrowers and what the federal government needs to do to tackle the student loan debt crisis.
Caroline Polisi, Criminal Defense Attorney & Lecturer in Law at Columbia Law School, breaks down the Holmes verdict and how this case impacts the reputation of female entrepreneurs.
The streaming wars picked up in 2021, but what can we expect to see in 2022 as the global economy re-opens? Wall Street is likely to spend much of the new year debating where to place bets in the new year, and specifically which entertainment stocks to focus on. Tuna Amobi, media and entertainment analyst at CFRA research, joins Cheddar News to share his top picks.
2022 is set to be a big year for autonomous technology. After many new partnerships, acquisitions, and developments in 2021, all eyes will be on the self-driving sector to see what progress, or lack there-of, will be made this year. Soroush Salehian, CEO and co-founder of Aeva, gives a look at what's ahead for the industry.
